Specific gene delivery mediated by poly(ethylene glycol)-grafted polyamidoamine dendrimer modified with a novel HER2-targeting nanobody

Abstract

As compared to other nanobiopolymers used in gene delivery applications, polyamidoamine dendrimers possess significantly improved physical and chemical properties such as monodispersity, well-defined size and shape, and biocompatibility, which make them ideal vectors for biomedical purposes. The aim of this study was fine-tuning of an anti–human epidermal growth factor receptor 2 (HER2) nanobody–polyethylene glycol (PEG)–G5 polyamidoamine gene delivery vector for potential in vivo applications. Polyethylene glycol was conjugated to polyamidoamine dendrimers at three different molar ratios of 10, 20, and 30 (polyethylene glycol:polyamidoamine). Anti-HER2 nanobody was chosen as our targeting agents and attached to polyethylene glycol–polyamidoamine conjugates. Cytotoxicity assays and transfection studies were carried out to find the most efficient conjugate in terms of both low cytotoxicity and high transfection rate. Our data indicated that PEGylation decreased the cytotoxicity of dendrimers alone and when complexed with DNA (dendriplexes). Among all of the polyethylene glycol–polyamidoamine dendrimers, polyethylene glycol(10)–polyamidoamine resulted in the most efficient gene transfection vector in both BT-474 and MCF-10A cell lines. Incorporation of anti-HER2 nanobodies could further increase their cellular uptake up to 1.7-fold compared to native dendrimers in HER2-overexpressing BT-474 cells but not in HER2-negative MCF-10A cells. It can be concluded from our results that nanobody–polyethylene glycol–polyamidoamine conjugates might be a promising new bioconjugate for the targeted gene delivery to HER2-positive tumor cells in vivo.

Keywords

Polyamidoamine dendrimer polyethylene glycol cytotoxicity HER2 nanobody

Get full access to this article

View all access options for this article.

References

Liu

Huang

. Development of non-viral vectors for systemic gene delivery. J Control Release 2002; 78: 259–266.

Yamano

Dai

Moursi

. Comparison of transfection efficiency of nonviral gene transfer reagents. Mol Biotechnol 2010; 46: 287–300.

Kukowska-Latallo

Bielinska

Johnson

. Efficient transfer of genetic material into mammalian cells using Starburst Polyamidoamine dendrimers. Proc Natl Acad Sci 1996; 93: 4897–4902.

Svenson

Tomalia

. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev 2005; 57: 2106–2129.

Duncan

Izzo

. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005; 57: 2215–2237.

Kolhatkar

Kitchens

Swaan

. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem 2007; 18: 2054–2060.

Wang

Xiong

Wan

. The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress. Nanotechnology 2009; 20: 105103.

Patri

Myc

Beals

. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004; 15: 1174–1181.

Thomas

Patri

Myc

. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules 2004; 5: 2269–2274.

10.

Shukla

Thomas

Peters

. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 2006; 17: 1109–1115.

11.

Gianni

Eiermann

Semiglazov

. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377–384.

12.

Altintas

Kok

Schiffelers

. Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. Eur J Pharm Sci 2012; 45: 399–407.

13.

Hamers-Casterman

Atarhouch

Muyldermans

. Naturally occurring antibodies devoid of light chains. Nature 1993; 363: 446–448.

14.

Nanobodies—from llamas to therapeutic proteins. Drug Discov Today Technol 2010; 7: e95–e146.

15.

Saerens

Ghassabeh

Muyldermans

. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008; 8: 600–608.

16.

Rahbarizadeh

Ahmadvand

Sharifzadeh

. Nanobody; an old concept and new vehicle for immunotargeting. Immunol Invest 2011; 40: 299–338.

17.

Rahbarizadeh

Jamnani

Iri-Sofla

. Nanobody, new agent for combating against breast cancer cells, Breast Cancer- Current and Alternative Therapeutic Modalities, Prof. Esra Gunduz (Ed.), ISBN: 978-953-307-776-5, InTech, DOI: 10.5772/22927.

18.

Oliveira

Heukers

Sornkom

. Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release 2013; 172: 607–617.

19.

Oliveira

Schiffelers

van der Veeken

. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release 2010; 145: 165–175.

20.

Sadeqzadeh

Rahbarizadeh

Ahmadvand

. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J Control Release 2011; 156:85–91.

21.

Jamnani

Rahbarizadeh

Shokrgozar

. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. Exp Cell Res 2012; 318: 1112–1124.

22.

Snyder

Sobocinski

. An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. Anal Biochem 1975; 64: 284–288.

23.

Gao

Tang

. PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression. AAPS J 2009; 11: 395–405.

24.

Zhu

Hong

Zhang

. PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res 2010; 27: 161–174.

25.

Santos

Pandita

Rodrigues

. Receptor-mediated gene delivery using PAMAM dendrimers conjugated with peptides recognized by mesenchymal stem cells. Mol Pharm 2010; 7: 763–774.

26.

Jevprasesphant

Penny

Attwood

. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res 2003; 20: 1543–1550.

27.

Fant

Esbjorner

Jenkins

. Effects of PEGylation and acetylation of PAMAM dendrimers on DNA binding, cytotoxicity and in vitro transfection efficiency. Mol Pharm 2010; 7: 1734–1746.

28.

Luo

Haverstick

Belcheva

. Poly(ethylene glycol)-conjugated PAMAM dendrimer for biocompatible, high efficiency DNA delivery. Macromolecules 2002; 35: 3456–3462.